Format

Send to

Choose Destination
Cancer Cell. 2012 Jan 17;21(1):7-9. doi: 10.1016/j.ccr.2011.12.017.

How to fool a wonder drug: truncate and dimerize.

Author information

1
Signal Transduction Laboratory, Cancer Research UK London Research Institute, UK.

Abstract

In a recent paper, Poulikakos et al. describe a new and potentially common mechanism whereby melanomas develop resistance to the BRAF inhibitor vemurafenib by expressing truncated forms of BRAF(V600E) that can dimerize in the absence of activated RAS. Will it be possible to block this with improved BRAF inhibitor design?

PMID:
22264784
DOI:
10.1016/j.ccr.2011.12.017
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center